STTK vs SYRE
STTK: Shattuck Labs is a clinical-stage biotech developing novel protein therapeutics to treat inflammatory and immune-mediated diseases by targeting the DR3/TL1A pathway. SYRE: Spyre is developing a portfolio of long-acting engineered antibodies and combinations targeting validated inflammatory pathways in IBD and rheumatic diseases with potential for quarterly dosing convenience.
Side-by-side fundamentals
| Metric | STTK | SYRE | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $7.04 | $100.04 | |
| Market cap as of 2026-07-30 | $540M | $8.7B | |
| Net margin as of 2026-07-30 | -1005.6% | -22158.5% | STTK higher |
| Operating margin as of 2026-07-30 | -1071.6% | -17559.3% | STTK higher |
| ROE as of 2026-07-30 | -60.7% | -31.3% | SYRE higher |
| ROA as of 2026-07-30 | -55.8% | -27.8% | SYRE higher |
| Debt / equity as of 2026-07-30 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-30 | -78.3% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +15.3% | n/a | |
| Beta as of 2026-07-30 | 1.00 | 2.94 | |
| 1-year return as of 2026-07-27 close | +732.2% | +462.3% | STTK higher |
Fundamentals: market data, as of 2026-07-30. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.